SCHEMBL2719084

SCHEMBL2719084

CC(NC(=O)O)c1ccc(OCC(F)(F)F)nc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
EPHX2 P34913 4/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
CYP2J2 P51589 1/20 0.50
POLB P06746 1/20 0.47
MAPK1 P28482 1/20 0.47
CACNA1G O43497 1/20 0.45
CACNA1H O95180 1/20 0.45
CNR2 P34972 1/20 0.45
KCNH2 Q12809 1/20 0.45
CACNA1I Q9P0X4 1/20 0.45
IDH1 O75874 1/20 0.44
ACACB O00763 6/20 0.44
MAPT P10636 1/20 0.44
CHRNA7 P36544 2/20 0.43
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
SCN5A Q14524 1/20 0.40
SCN9A Q15858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28389390 0.85 L3MBTL1 (0.47) L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2
SCHEMBL27931799 0.83 L3MBTL1 (0.48) L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2
SCHEMBL2718737 0.83 L3MBTL1 (0.53) L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2
SCHEMBL2716606 0.83 L3MBTL1 (0.50) L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2
SCHEMBL2133892 0.82 NR1H4 (0.54) L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2
SCHEMBL2133898 0.82 NR1H4 (0.54) L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2
SCHEMBL27931768 0.82 EPHX2 (0.42) L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2
SCHEMBL27931836 0.82 EPHX2 (0.46) L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2
SCHEMBL28806898 0.82 PDE2A (0.43) L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2
SCHEMBL28129477 0.82 EPHX2 (0.42) L3MBTL1EPHX2CYP2C9CYP2C19CYP2J2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP disclosed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN2B, SCN1B, SCN2A L3MBTL1 2429/4885EPHX2 2460/4885CYP2C9 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.